Projecting the COPD population and costs in England and Scotland: 2011 to 2030

Susannah McLean, Martine Hoogendoorn, Rudolf T Hoogenveen, Talitha L Feenstra, Sarah Wild, Colin R Simpson, Maureen Rutten-van Molken, Aziz Sheikh

Research output: Contribution to journalArticlepeer-review


We aimed to estimate the prevalence, healthcare costs and number of deaths among people with chronic obstructive pulmonary disease (COPD) in England and Scotland 2011-2030. We adapted the Dutch COPD Model by using English and Scottish demographic, COPD incidence, COPD prevalence, smoking prevalence and mortality data to make projections. In England, the prevalence of COPD was estimated to be 1.79% (95% uncertainty interval 1.77-1.81) in 2011, increasing to 2.19% (1.85-2.33) by 2030. In Scotland, prevalence was 2.03% (1.96-2.10) in 2011 increasing to 2.20% (1.98-2.40) in 2030. These increases were driven by more women developing COPD. Annual direct healthcare costs of COPD in England were estimated to increase from £1.50 billon (1.18-2.50) in 2011 to £2.32 (1.85-3.08) billion in 2030. In Scotland, costs increased from £159 million (128-268) in 2011 to £207 (165-274) million in 2030. The deaths in England were estimated to increase from 99,200 (92500-128500) in 2011, to 129,400 (126400-133400) by 2030. In Scotland, in 2011 there were 9,700 (9000-12300) deaths and 13,900 (13,400-14,500) deaths in 2030. The number of people with COPD will increase substantially over the coming years in England and Scotland, particularly in females. Services need to adapt to this increasing demand.
Original languageEnglish
JournalScientific Reports
Issue number31893
Publication statusPublished - 1 Sep 2016


Dive into the research topics of 'Projecting the COPD population and costs in England and Scotland: 2011 to 2030'. Together they form a unique fingerprint.

Cite this